1. Home
  2. FT vs TVGN Comparison

FT vs TVGN Comparison

Compare FT & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$7.88

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

HOLD

Current Price

$6.35

Market Cap

21.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
TVGN
Founded
1988
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Blank Checks
Sector
Finance
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
21.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FT
TVGN
Price
$7.88
$6.35
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
36.1K
10.9K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.79
$0.14
52 Week High
$8.35
$12.03

Technical Indicators

Market Signals
Indicator
FT
TVGN
Relative Strength Index (RSI) 41.88 53.88
Support Level $7.84 $6.33
Resistance Level $8.08 $7.42
Average True Range (ATR) 0.05 0.66
MACD -0.00 0.13
Stochastic Oscillator 33.76 68.35

Price Performance

Historical Comparison
FT
TVGN

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.

Share on Social Networks: